We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Supernus Pharmaceuticals Inc | NASDAQ:SUPN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.41 | -1.33% | 30.42 | 29.41 | 31.47 | 31.405 | 30.14 | 31.04 | 335,111 | 23:20:54 |
From May 2019 to May 2024
| Stifel 2015 Healthcare Conference |
| Presentation Date: Tuesday, November 17th |
| Presentation Time: 4:30 PM ET |
| Place: The New York Palace Hotel, New York |
| Piper Jaffray 27th Annual Healthcare Conference |
| Presentation Date: Tuesday, December 1st |
| Presentation Time: 10:30 AM ET |
| Place: The New York Palace Hotel, New York |
Investors interested in arranging a meeting with the Company's management during these conferences should contact the respective conference coordinator.
A live webcast of the presentations can be accessed by visiting 'Events & Presentations' in the Investors Section on the Company's website at www.supernus.com. An archived replay of each webcast will be available for 60 days on the Company's website following the conferences.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of impulsive aggression in patients with ADHD in conjunction with standard ADHD treatment, and SPN-812 for ADHD.
Hot Features
Premium
CONTACT: Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
Or
Investor Contact:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
1 Year Supernus Pharmaceuticals Chart |
1 Month Supernus Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
